New timing strategy tested to boost chemo against advanced pancreatic cancer
NCT ID NCT04115163
Summary
This study is testing whether changing the timing of two standard chemotherapy drugs (gemcitabine and nab-paclitaxel) can improve treatment for pancreatic cancer that has spread. The goal is to see if this adjusted schedule helps shrink tumors better and is tolerable for patients. The trial will enroll about 67 adults with newly diagnosed metastatic pancreatic cancer who have not yet received chemotherapy for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.